Genmab

CEO - Jan van de Winkel
CEO - Jan van de Winkel
Denmark | Funding: $204.3M (+)

Website: http://www.genmab.com/

Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.